TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
12.26
-0.43 (-3.43%)
As of 1:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close12.69
Open12.60
Bid12.26 x 2200
Ask12.27 x 2200
Day's range12.16 - 12.61
52-week range6.07 - 13.76
Volume5,438,610
Avg. volume10,812,106
Market cap13.001B
Beta (5Y monthly)1.66
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target estN/A
  • Got $1,000? Buy These 4 Beaten-Down Stocks Right Now
    Motley Fool

    Got $1,000? Buy These 4 Beaten-Down Stocks Right Now

    Amid record-breaking levels of volatility, we've witnessed the S&P 500 lose more than a third of its value in a five-week stretch, as well as the technology-dependent Nasdaq Composite set more than two dozen all-time closing highs. Despite inevitable stock market corrections and bear markets, the S&P 500 has historically gained 7% per year, inclusive of dividend reinvestment. One of the hardest-hit industries during the coronavirus crash were bank stocks, with Wells Fargo (NYSE: WFC) leading the way to the downside among money-center banks.

  • The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries
    Zacks

    The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries

    The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries

  • Sometimes, Valuation Is the Most Important Consideration
    Zacks

    Sometimes, Valuation Is the Most Important Consideration

    It pays to check the valuation before investing because it isn't always the best companies that have upside potential.

  • Warren Buffett's 3 Biggest Winners in the First Half of 2020: Are They Still Buys Now?
    Motley Fool

    Warren Buffett's 3 Biggest Winners in the First Half of 2020: Are They Still Buys Now?

    Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) shares fell 21% in the first six months of the year. Most of the stocks in Berkshire's investment portfolio were down as well. Here are Warren Buffett's three biggest winners in the first half of 2020 -- and whether or not they're still great stocks to buy for investors who aren't yet legends.

  • Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H
    Zacks

    Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H

    Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.

  • Choose These 5 Price-to-Book Value Stocks for High Returns
    Zacks

    Choose These 5 Price-to-Book Value Stocks for High Returns

    P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

  • Here's My Single Best Investment Idea for July
    Motley Fool

    Here's My Single Best Investment Idea for July

    Thus far in 2020, we've witnessed the fastest bear-market decline in history, a record-breaking volatility reading, courtesy of the CBOE Volatility Index, and one of the most ferocious rebound rallies from a bear-market low. As we begin our descent toward the latter half of 2020, I'd like to introduce you to my single best investment idea for the month of July: brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE: TEVA). Take a quick peek at Teva's five-year chart, and most investors would probably make a beeline for the exit.

  • Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?
    Zacks

    Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • My Top 5 Portfolio Holdings for the Second Half of 2020
    Motley Fool

    My Top 5 Portfolio Holdings for the Second Half of 2020

    These are the stocks that might power one Fool's portfolio higher for the remainder of the year.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $11.25, moving -0.71% from the previous trading session.

  • 3 Buffett Stocks That Are Still Historically Cheap
    Motley Fool

    3 Buffett Stocks That Are Still Historically Cheap

    Even with a 40% bounce off of the stock market's lows, these companies still offer incredible value.

  • EU antitrust regulators reinforce case against Teva pay-for-delay deals
    Reuters

    EU antitrust regulators reinforce case against Teva pay-for-delay deals

    EU antitrust enforcers, boosted by recent court victories, on Monday reinforced their case against Israeli drugmaker Teva <TEVA.TA> over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil. Three years ago, the European Commission said the company's cash payments deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the blockbuster drug may have jacked up the price of modafinil.

  • 3 Buffett Stocks That Are Trouncing Berkshire Hathaway So Far This Year
    Motley Fool

    3 Buffett Stocks That Are Trouncing Berkshire Hathaway So Far This Year

    Three Buffett stocks, in particular, are trouncing Berkshire in 2020. While the COVID-19 pandemic has hurt many companies, Amazon's business has thrived. The impact of the global novel coronavirus outbreak has turned Amazon's business upside down -- mostly in a good way.

  • 2 Pharmaceutical Stocks Trading Below Their Book Value
    Motley Fool

    2 Pharmaceutical Stocks Trading Below Their Book Value

    Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.

  • Is Teva Pharmaceuticals Stock a Buy?
    Motley Fool

    Is Teva Pharmaceuticals Stock a Buy?

    Teva Pharmaceutical Industries (NYSE: TEVA) is a well known generic drugmaker that's attracted the attention of a number of well-known investors in the past. Most notably, Warren Buffett's Berkshire Hathaway bought shares of the company a number of years ago due, in no small part due to how cheap the stock was at the time. Teva's business can be split up into two main areas: its generics business and its own branded drug products.

  • Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
    Zacks

    Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought
    Motley Fool

    Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought

    No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.

  • Can Teva (TEVA) Return to Growth in This Year or Next?
    Zacks

    Can Teva (TEVA) Return to Growth in This Year or Next?

    Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

  • 3 Absolutely No-Brainer Bear Market Buys
    Motley Fool

    3 Absolutely No-Brainer Bear Market Buys

    Beginning in late February, we witnessed the broad-based S&P 500 endure the fastest descent into bear market territory in history -- it took a little over three weeks. Every bear market correction in history has proved to be an excellent buying opportunity for long-term-minded investors. This means that if you buy businesses with game-changing potential at a discount during a bear market, you'll be setting yourself up to make a lot of money.

  • Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?
    Zacks

    Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to today's Teva Pharmaceutical First Quarter 2020 Financial Results. Delay, I would now like to hand the conference over to presenter today, Kevin Mannix, Senior Vice President and Head of Investor Relations. Thank you, operator, and thank you, everyone, for joining us today to discuss Teva's First Quarter 2020 Financial Results.

  • Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
    Zacks

    Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

    Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

  • Here's Why Teva Pharmaceuticals Jumped Higher Today
    Motley Fool

    Here's Why Teva Pharmaceuticals Jumped Higher Today

    Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are up 11% at 1:50 p.m. EDT after the drugmaker announced first-quarter earnings that beat expectations. For most drugmakers, 5% growth would be a slow quarter, but Teva has been struggling of late, with its multiple sclerosis drug Copaxone facing generic competition and a decline in its U.S. generic business, which resulted in revenue falling 8% year over year -- 5% in local currency terms -- in 2019. On the non-COVID-19 plus side, U.S. sales of Austedo, which treats tardive dyskinesia and Huntington's disease chorea, were up 64% year over year to $122 million.

  • Teva (TEVA) Q1 Earnings & Sales Beat Estimates, Stock Up
    Zacks

    Teva (TEVA) Q1 Earnings & Sales Beat Estimates, Stock Up

    Teva beats estimates for earnings and sales in first-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.